There is controversy on the use of Angiotensin Converting Enzyme Inhibitors (ACE-I) for advanced Chronic Kidney Disease (CKD)patients. Also, there are very meager reports on the evaluation of ACE-I for CKD in an advanced stage. The present article has summarized the data of a study that evaluate the benefit versus risk of these inhibitors for Stage-5 CKD patients. Introduction: Currently, over two million people require renal replacement therapy worldwide.
Proper management of CKD at any stage needs an understanding of the prognostic factors. In the early stages of CKD, proteinuria plays a major role among the progression factors and it is well established that inhibitors of the renin-angiotensin-aldosterone system (RAAS) induce renoprotection in this stage. However, there are very few reports on the role of angiotensin-converting enzyme (ACE) inhibitors (ACE-I) in very advanced CKD.…
